Evidence map›Paper›PMID 37896211›Full record

ReviewPharmaceutics2023

Topoisomeric Membrane-Active Peptides: A Review of the Last Two Decades.

Adam Carrera-Aubesart, Maria Gallo, Sira Defaus, Toni Todorovski, David Andreu

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Adam Carrera-AubesartDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.
Maria GalloDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.ORCID 0000-0001-9099-7235
Sira DefausDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.ORCID 0000-0002-3106-458X
Toni TodorovskiDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.ORCID 0000-0002-9168-2830
David AndreuDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.ORCID 0000-0002-6317-6666
Universitat Pompeu Fabra · ESUniversity of Rijeka · HR

Funding

European Union H2020-FETOPEN-2018-2019-2020-01 grant no 828774La Caixa Health Foundation HR17_00409
6 · The paper itself

Abstract

In recent decades, bioactive peptides have been gaining recognition in various biomedical areas, such as intracellular drug delivery (cell-penetrating peptides, CPPs) or anti-infective action (antimicrobial peptides, AMPs), closely associated to their distinct mode of interaction with biological membranes. Exploiting the interaction of membrane-active peptides with diverse targets (healthy, tumoral, bacterial or parasitic cell membranes) is opening encouraging prospects for peptides in therapeutics. However, ordinary peptides formed by L-amino acids are easily decomposed by proteases in biological fluids. One way to sidestep this limitation is to use topoisomers, namely versions of the peptide made up of D-amino acids in either canonic (enantio) or inverted (retroenantio) sequence. Rearranging peptide sequences in this fashion provides a certain degree of native structure mimicry that, in appropriate contexts, may deliver desirable biological activity while avoiding protease degradation. In this review, we will focus on recent accounts of membrane-active topoisomeric peptides with therapeutic applications as CPP drug delivery vectors, or as antimicrobial and anticancer candidates. We will also discuss the most common modes of interaction of these peptides with their membrane targets.

Indexed as

anticancer peptidesantimicrobial peptidescell-penetrating peptidesenantiomembrane-active peptidesretroretroenantiotopoisomery

Identifiers

PMID37896211
PMCPMC10610229
OpenAlexW4387578279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.